Skip to main navigation Skip to search Skip to main content

Leveraging lessons learned from the COVID-19 pandemic for HIV

  • Thomas Calder
  • , Tina Tong
  • , Dale J. Hu
  • , Jerome H. Kim
  • , Karen L. Kotloff
  • , Richard A. Koup
  • , Mary A. Marovich
  • , M. Juliana McElrath
  • , Sarah W. Read
  • , Merlin L. Robb
  • , Philip O. Renzullo
  • , M. Patricia D’Souza*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

The rapid development of COVID-19 vaccines and their deployment in less than a year is an unprecedented scientific, medical, and public health achievement. This rapid development leveraged knowledge from decades of HIV/AIDS research and advances. However, the search for an HIV vaccine that would contribute to a durable end to the HIV pandemic remains elusive. Here, we draw from the US government experience and highlight lessons learned from COVID-19 vaccine development, which include the importance of public-private partnerships, equitable inclusion of populations impacted by the infectious pathogen, and continued investment in basic research. We summarize key considerations for an accelerated and re-energized framework for developing a safe and efficacious HIV vaccine.

Original languageEnglish
Article number110
JournalCommunications Medicine
Volume2
Issue number1
DOIs
StatePublished - 1 Dec 2022

Fingerprint

Dive into the research topics of 'Leveraging lessons learned from the COVID-19 pandemic for HIV'. Together they form a unique fingerprint.

Cite this